Current Treatment Options in Gastroenterology

, Volume 12, Issue 2, pp 211–228

Update on Recently Approved Treatments for Hepatitis C

  • Daniel Chao
  • Gregory J. Botwin
  • Timothy R. Morgan
Liver (J Bajaj, Section Editor)

Opinion statement

Chronic hepatitis C virus (HCV) infection affects millions of individuals and is a significant cause of chronic liver disease and cirrhosis. Early treatment regimens relied on an immune-mediated response caused by interferon and only recently have medications acting directly on viral structures been discovered. In December 2013, two new medications, sofosbuvir and simeprevir, were approved by the US Food and Drug Administration (FDA) for treatment of chronic hepatitis C. This article reviews the approved treatment protocols for these two new medications and the clinical trials that fueled their development.

Keywords

Hepatitis C treatment Sofosbuvir Simeprevir 

Abbreviations

BOC

Boceprevir

FDA

US Food and Drug Administration

GT

Genotype

HCV

Hepatitis C virus

IFN

Interferon

NI

Nucleos(t)ide inhibitor

NNI

Non-nucleos(t)ide inhibitor

NS

Non-structural

PegIFN

Pegylated interferon

PI

Protease inhibitor

RBV

Ribavirin

SMV

Simeprevir

SOF

Sofosbuvir

SVR

Sustained virologic response

TPV

Telaprevir

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090–101.PubMedCrossRefGoogle Scholar
  2. 2.
    Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315(25):1575–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Terrault N, Wright T. Interferon and hepatitis C virus infection. N Engl J Med. 1995;332(22):1509–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Swain MG, Lai MY, Shiffman ML, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139(5):1593.PubMedCrossRefGoogle Scholar
  5. 5.
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Manns MP, Markova AA, Serrano BC, Cornberg M. Phase III results of boceprevir in treatment naive patients with chronic hepatitis C genotype 1. Liver Int. 2012;32 Suppl 1:29–31.Google Scholar
  8. 8.
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–17.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2406–16.CrossRefGoogle Scholar
  10. 10.
    McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010;362(14):1292–303.PubMedCrossRefGoogle Scholar
  11. 11.
    Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Buti M, Agarwal K, Horsmans Y et al. Telaprevir twice daily is noninferior to telaprevir every 8 hrs for patients with chronic hepatitis C. Gastroenterology. 2014;1–10.Google Scholar
  13. 13.
    Flamm S, Chopra S. Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection. UpToDate; 2013 [updated Jan 23, 2013; cited Nov 25, 2013]. Available from: http://www.uptodate.com/contents/mechanism-of-action-and-efficacy-of-ribavirin-for-the-treatment-of-chronic-hepatitis-c-virus-infection?source=search_result&search=ribavirin&selectedTitle=5%7E150. Accessed 25 Nov 2013.
  14. 14.
    Lindenbach BD, Rice CM. Unravelling hepatitis C virus replication from genome to function. Nature. 2005;436(7053):933–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58(1):428–38.PubMedCrossRefGoogle Scholar
  16. 16.
    www.fda.gov [homepage on the Internet]. Approval of Sovaldi (sofosbuvir) tablets for the treatment of chronic hepatitis C for consumers. US Food and Drug Administration; 2013 [updated 12/07/13, cited 12/25/13]. Available from: http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/ucm377920.htm. Accessed 25 Dec 2013.
  17. 17.•
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. This article includes all of the results from NEUTRINO and FISSION, the two phase III trials that together investigated response to SOF treatment regimens in treatment-naive patients with all six HCV genotypes.PubMedCrossRefGoogle Scholar
  18. 18.•
    Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77. This article includes all of the results from POSITRON and FUSION, phase III trials that treated patients with SOF who had chronic genotype 2 or 3 HCV infection and either could not receive interferon-based therapy or had poor responses to a previous course of interferon-based therapy.PubMedCrossRefGoogle Scholar
  19. 19.
    www.natap.org [homepage on the Internet]. Conference reports: 64rd [sic] Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1–5 2013. Reported by Jules Levin. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3; the VALENCE trial. National AIDS Treatment Advocacy Project; 2013 [cited Nov 4, 2013]. Available from: http://www.natap.org/2013/AASLD/AASLD_15.htm. Accessed 2 Jan 2014.
  20. 20.
    www.fda.gov [homepage on the Internet]. Birnkrant D, Mishra P, Florian J, Qi K. Presentations for the October 25, 2013 meeting of the Antiviral Drugs Advisory Committee: sofosbuvir NDA 204671 [slideset]. US Food and Drug Administration; 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM375285.pdf. Accessed 11 Jan 2014.
  21. 21.
    www.fda.gov [homepage on the Internet]. FDA Antiviral Drugs Advisory Committee meeting background package for NDA 204671: sofosbuvir (GS-7977) Oct 25, 2013. US Food and Drug Administration; 2013.Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371876.pdf. Accessed 11 Jan 2014.
  22. 22.
    www.fda.gov [homepage on the Internet]. Olysio (simeprevir) for the treatment of chronic hepatitis C in combination antiviral treatment. US Food and Drug Administration 2013 [updated 12/02/13, cited 1/11/14]. Available from: http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ucm377234.htm. Accessed 11 Jan 2014.
  23. 23.
    www.fda.gov [homepage on the Internet]. FDA Antiviral Drugs Advisory Committee meeting background package for NDA 205123: simeprevir (TMC435) Oct 24, 2013. US Food and Drug Administration; 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM371623.pdf. Accessed 11 Jan 2014.
  24. 24.
    www.fda.gov [homepage on the Internet]. Sherwat A. Presentations for the October 24, 2013 Antiviral Drugs Advisory Committee meeting: simeprevir (TMC435) [slideset]. US Food and Drug Administration 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM375113.pdf. Accessed 11 Jan 2014.
  25. 25.
    Jacobson I, Dore GJ, Foster GR, et al. Late breaking abstracts: 1425. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a phase III trial. J Hepatol. 2013;58:S574.CrossRefGoogle Scholar
  26. 26.
    Manns M, Marcellin P, Poordad FP, et al. Late breaking abstracts: 1413. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol. 2013;58:S568.CrossRefGoogle Scholar
  27. 27.
    Lawitz E, Forns X, Zeuzem S, et al. AGA abstracts: 869b. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial. AGA Abstracts. 2013;S–151.Google Scholar
  28. 28.
    Lenz O, Fevery B, Vijgen L, et al. TMC 435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analysis of the ASPIRE trial. 47th Annual Meeting of the European Association for the Study of the Liver; 2012 April 18-22; Barcelona, Spain. Abstract 9.Google Scholar
  29. 29.
    www.fda.gov [homepage on the Internet]. Picchio G, Afdhal NH, Boven K, Beumont M, Lenz O, Jessner W. Janssen main presentations for the October 24, 2013 meeting of the Antiviral Drugs Advisory Committee: simeprevir (TMC435). [slideset] US Food and Drug Administration 2013. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AntiviralDrugsAdvisoryCommittee/UCM375115.pdf. Accessed 11 Jan 2014.
  30. 30.
    www.natap.gov [homepage on the Internet]. 64rd [sic] Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5, 2013. Reported by Jules Levin. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. National AIDS Treatment Advocacy Project; 2013 [cited 11/05/13]. Available from: http://www.natap.org/2013/AASLD/AASLD_24.htm. Accessed 11 Jan 2014.
  31. 31.
    www.gilead.com [homepage on the Internet]. US Food and Drug Administration approves Gilead's Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C. Dec 6, 2013. Available from: http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c. Accessed 1 Feb 2014.
  32. 32.
    www.fairpricingcoalition.org [homepage on the Internet]. Fair Pricing Coalition disappointed by the high price of new Janssen hepatitis C drug Olysio (simeprevir). Nov 28, 2013. Available from: http://fairpricingcoalition.org/2013/11/28/fair-pricing-coalition-disappointed-by-the-high-price-of-new-janssen-hepatitis-c-drug-olysio-simeprevir/. Accessed 1 Feb 2014.

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2014

Authors and Affiliations

  • Daniel Chao
    • 1
    • 2
  • Gregory J. Botwin
    • 1
  • Timothy R. Morgan
    • 1
    • 2
  1. 1.Gastroenterology SectionVA Long Beach Healthcare System-11Long BeachUSA
  2. 2.Division of GastroenterologyUniversity of CaliforniaIrvineUSA

Personalised recommendations